Asymmetric synthesis of active pharmaceutical ingredients

被引:451
|
作者
Farina, Vittorio [1 ]
Reeves, Jonathan T. [1 ]
Senanayake, Chris H. [1 ]
Song, Jinhua J. [1 ]
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Dept Chem Dev, Ridgefield, CT 06877 USA
关键词
D O I
10.1021/cr040700c
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Over the years, a wide range of stereoselective synthetic methods have found applications in the large-scale asymmetric synthesis of active pharmaceutical ingredients (APIs). As a result, industrial process chemists have come to appreciate the value of these catalytic methods for the development of cost-effective, scalable, and environmentally sound processes, and have started to integrate these technologies into many API syntheses. In addition to a few well-established asymmetric catalytic protocols such as asymmetric hydrogenation and asymmetric epoxidation, many other types of catalytic transformations, such as asymmetric C-C bond-forming and dynamic kinetic resolution approaches, are slowly beginning to be incorporated into the large-scale synthesis of APIs.
引用
收藏
页码:2734 / 2793
页数:60
相关论文
共 50 条
  • [1] Biocatalysis for the asymmetric synthesis of Active Pharmaceutical Ingredients (APIs): this time is for real
    de Gonzalo, Gonzalo
    Alcantara, Andres R.
    Dominguez de Maria, Pablo
    Maria Sanchez-Montero, Jose
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (10) : 1159 - 1171
  • [2] Continuous flow asymmetric synthesis of chiral active pharmaceutical ingredients and their advanced intermediates
    Otvos, Sandor B.
    Kappe, C. Oliver
    GREEN CHEMISTRY, 2021, 23 (17) : 6117 - 6138
  • [3] Multicomponent Reactions for the Synthesis of Active Pharmaceutical Ingredients
    Cores, Angel
    Clerigue, Jose
    Orocio-Rodriguez, Emmanuel
    Carlos Menendez, J.
    PHARMACEUTICALS, 2022, 15 (08)
  • [4] Asymmetric organocatalysis in drug discovery and development for active pharmaceutical ingredients
    Burke, Anthony J.
    EXPERT OPINION ON DRUG DISCOVERY, 2023, 18 (01) : 37 - 46
  • [5] Engineered MOFs and Enzymes for the Synthesis of Active Pharmaceutical Ingredients
    Cirujano, Francisco G.
    CHEMCATCHEM, 2019, 11 (23) : 5671 - 5685
  • [6] A systematic reactor design approach for the synthesis of active pharmaceutical ingredients
    Emenike, Victor N.
    Schenkendorf, Rene
    Krewer, Ulrike
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2018, 126 : 75 - 88
  • [7] Boric acid catalyzed amidation in the synthesis of active pharmaceutical ingredients
    Mylavarapu, Ravi Kumar
    Kondaiah, G. C. M.
    Kolla, Naveenkumar
    Veeramalla, Raju
    Koilkonda, Purandhar
    Bhattacharya, Apurba
    Bandichhor, Rakeshwar
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2007, 11 (06) : 1065 - 1068
  • [8] Polymorphism of active pharmaceutical ingredients
    Karpinski, PH
    CHEMICAL ENGINEERING & TECHNOLOGY, 2006, 29 (02) : 233 - 237
  • [9] Prequalification of active pharmaceutical ingredients
    WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS, 2015, 992 : 37 - 37
  • [10] Prequalification of active pharmaceutical ingredients
    WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS, 2013, 981 : 29 - 29